DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



[Frusemide plus doxazosin therapy for nocturia in patients with BPH/LUTS].

Author(s): Huang SY, Zhu SX, Zeng BW, Zhu DS, Fang RJ

Affiliation(s): Department of Urology, Union Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian 350001, China. monkeytreeh4y@sina.com

Publication date & source: 2010-09, Zhonghua Nan Ke Xue., 16(9):807-10.

Publication type: English Abstract; Randomized Controlled Trial

OBJECTIVE: To determine the efficacy and safety of a diuretic agent, frusemide, combined with doxazosin in the treatment of nocturia in patients with benign prostate hyperplasia / lower urinary tract symptoms (BPH/LUTS). METHODS: Sixty-four BPH/LUTS patients with nocturia were equally randomized into two groups, one treated with doxazosin (4 mg/d), and the other with frusemide (40 mg/d) and doxazosin (4 mg/d), given 6 h before sleep, both for 4 weeks. Urine volume, IPSS, QOL, serum electrolytes, plasma osmolality were recorded and compared between the two groups before and after the treatment. RESULTS: Compared with the doxazosin group, the frusemide plus doxazosin group showed significantly reduced nocturia frequency (P < 0.01), increased daytime urine output (P < 0.01), decreased nocturia urine output (P < 0.01), unchanged total urine output (P > 0.05), improved IPSS and QOL (P < 0.05, P < 0.01), but with no remarkable differences in the levels of serum sodium, potassium, chlorine, and osmotic pressure (P > 0.05). CONCLUSION: Four-week treatment with frusemide plus doxazosin was safe and effective for nocturia in patients with BPH/LUTS.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017